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Abstract 
The dynamic field of neurosciences entails ever increasing search for molecular mechanisms of disease states, 
especially in the domain of neurodegenerative disorders. The previous century heralded the techniques in proteom-
ics when indexing of the human proteomes relating to various disease conditions became important. Early stage 
research in certain diseases or pathological conditions requires a more holistic approach of first discovering the pro-
teins of interest for the condition. Despite its limitations, proteomics is one of the most powerful techniques available 
to us today to dissect the molecular scenario in a particular disease situation. In this review we will discuss about the 
current clinical research in neurodegenerative disorders that employ proteomics techniques. We will specifically focus 
on our understanding of Alzheimer’s disease, traumatic spinal cord injury and neuromyelitis optica. Discussions will 
include ongoing worldwide research in these areas, research in India and specifically our laboratory in these domains 
of neurodegenerative conditions.
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Background
The most polarized cells of the human body, neurons, are 
a specialized type with respect to their functional prop-
erties. Development and function of neurons are closely 
linked to the bidirectional transport of molecules from 
the synaptic end to the cell body. This very synaptic sig-
nal, which when disrupted, causes the dysfunction of 
neuronal activities. Disruption in axonal transport is the 
cause of several neurodegenerative disorders [1, 2]. In the 
realm of peripheral neuron injury, retrograde transport 
of molecules from the site of injury to the cell body of a 
peripheral neuron primes the latter to regenerate [3, 4]. 
This phenomenon is absent in the central nervous system 
(CNS), with the consequence of regeneration after CNS 
injury being elusive even with years of research. Partly 
because of the large distance separating the axon end 
from the cell body, many molecular events after a trauma 
or a neuronal disease occur without any transcriptional 
manifestations [5]. Local proteolysis, protein synthesis 
and post translational modifications are the key to under-
standing axonal events after an assault or a disorder of 
the neuron [5]. Proteomics approaches have therefore 
come to the limelight in recent times. In this review, we 
will discuss the contributions of our group from this per-
spective and also the prospective ideas in three neurolog-
ical degenerative situations, namely Alzheimer’s disease 
(AD), traumatic spinal cord injury (SCI) and neuromy-
elitis optica (NMO) and explore the advances in under-
standing these pathological processes using proteomics 
approaches.
Ethics statement
The data provided in the review was collected by a joint 
collaborative study of SINP and NRSMC&H, Kolkata, 
India, after it was approved by Institutional Ethical Com-
mittees. An informed written consent was obtained from 
the subjects as per Helsinki Declaration, 2013.
Clinical proteomics in AD
During the past few years Mass spectrometry (MS) based 
proteomics tools have been used extensively to study AD-
related proteome changes in blood (plasma and serum), 
cerebrospinal fluid (CSF) samples and in postmortem 
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brain tissues [6]. Since the pathological processes of AD 
start decades before the first symptoms appear, the objec-
tive of all AD proteomics studies have been to identify 
precisely the early diagnostic and prognostic biomarkers. 
Here we review reports that have used diverse samples 
including blood, CSF, brain tissues and also discuss dif-
ferent aspects of proteome status like posttranslational 
modifications (PTMs), redox proteomics and interaction 
proteomics.
Blood and CSF proteomics studies are being done for 
more than a decade to identify AD-related biomarkers, 
of which the most widely researched one is the peptide 
Amyloid β (Aβ). Utility of Aβ as a predictor of demen-
tia and AD is well established and it is evident that lower 
Aβ42:Aβ40 ratios are mainly associated with the disease 
[7]. In 2007, a plasma proteomic study in AD patients 
identified six potential plasma biomarkers using 2D-GE 
and LC/MS/MS [8]. Some of them, for example α-1 anti-
trypsin, could be validated for its higher expression level 
in plasma of AD patients using ELISA. Apolipoprotein 
J was found to be in lower abundance in plasma of AD 
patients in an isoform-specific manner. This observa-
tion could only be achieved through 2-DE but could not 
be validated through biochemical methods like ELISA 
or Western blot. Recently, a large scale replication study 
was conducted for 94 proteins out of 163 potential candi-
date biomarkers found in 21 published blood proteomics 
studies. 9 were found to be associated with AD-related 
phenotypes [9]. It was concluded that there are repli-
cable changes in proteomic expressions in blood of AD 
patients that can be identified by different studies with 
some consistency.
The rationale of studying plasma and CSF biomarkers 
for AD has been explicitly reviewed [10] and the diagnos-
tic performance of the core CSF biomarkers, namely total 
tau, phosphorylated tau and Aβ-42 has been discussed. 
But studying these traditional biomarkers is not suffi-
cient to identify preclinical AD. Study of differential pro-
teome from whole tissue/body fluids in the disease model 
compared to that of the normal control is of immense 
importance in order to identify key, novel protein can-
didates for the disease. Recently, combination of Aβ, tau 
and p-tau along with several novel biomarkers in CSF 
have been used extensively for diagnostic confirmation of 
AD [11]. It is realized that co-development of biomark-
ers for early diagnosis and novel therapeutic approaches, 
together could be the way to go.
A recent review has extensively discussed the features 
of neurodegeneration proteomics and its importance in 
relation to PTM [12]. Evaluation of functional alterations 
in proteins due to PTMs can be achieved by means of a 
battery of proteomic tools. For the elucidation of patho-
genic mechanisms, study of PTMs in AD is of immense 
importance and would become the future of proteomics 
research to understand the disease process. Very recently, 
the CSF glycoproteome was studied as a fingerprint of the 
brain glycoproteome of AD patients [13] and it is con-
cluded that CSF N-glycome analysis may provide reliable 
biomarkers for early diagnosis of the disease. In many 
studies, proteins from CSF of AD patients are shown to 
have differential isoforms in terms of glycosylation [14], 
S-nitrosylation [15] and histone protein modifications 
[16] in different tissue sections of the AD brain. Recently 
quantitative phosphoproteomics studies in the frontal 
cortex [17] and hippocampi [18] of AD brains have deci-
phered the deregulation of biological pathways in AD 
due to alteration in the PTM status. A more recent study 
deals with changes in protein phosphorylation status 
in the inferior parietal lobule of subjects with different 
stages of the disease (AD, Mild Cognitive Impairment, 
MCI, Pre-Clinical Alzheimer’s Disease, PCAD) and con-
trol brain [19]. Phosphorylation status of nineteen pro-
teins is found to be different in these stages of the disease. 
These proteins are involved in energy metabolism, neu-
ronal plasticity, signal transduction and oxidative stress 
response. The same group has studied and discussed 
the effects of Aβ-induced oxidative stress, its redox pro-
teomics and its importance in disease pathology and 
progression [20, 21]. Also, selectively oxidized proteins 
namely, creatine kinase BB, glutamine synthase, ubiqui-
tin carboxy-terminal hydrolase L-1, alpha-enolase, triose 
phosphate isomerase and neuropolypeptide h3 in human 
samples were identified and can be studied in future to 
understand the AD pathogenesis better [22, 23]. Redox 
proteomics analysis has been conducted to identify spe-
cific carbonylated proteins (for example, alpha-enolase, 
glutamine synthetase, protein disulfide isomerase A3 
etc.) in the hippocampus at the very early stage in AD 
mouse model [24].
A recent study with micro dissected neurons from the 
temporal cortex of AD brain has identified more than 400 
proteins using LC–MS analysis [25]. Several recent stud-
ies have dealt with targeted and localized quantitative 
proteomics in presynaptic and postsynaptic tissue sam-
ples in AD and have identified a large number of proteins 
relevant to the disease process [26–28]. All these studies 
aim at identifying novel candidates or imprints for early 
diagnosis of a neurodegenerative condition like AD.
AD clinical proteomics in India: Interaction 
proteomics with focus on APP intracellular  
domain (AICD)
There have not been many studies in the domain of 
Alzheimer’s disease research employing proteomics 
approach. Although there are extensive reviews discuss-
ing employment of proteomics for biomarker discovery 
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in neuropsychiatric disorders [29] and of the relation of 
AD and type-2 diabetes [30], only one clinical proteom-
ics study with AD CSF samples has been conducted [31]. 
This study has found Apolipoprotein E, Apolipoprotein J, 
Hemopexin, Complement factor b and complement C4b 
to be differentially abundant in AD versus control CSF 
samples.
Our laboratory focuses on interaction proteomics of 
amyloid precursor protein (APP) intracellular domain 
(AICD). AICD generated by post γ-secretase cleavage of 
APP has been an important molecule of the AD pathway 
and has drawn the focus of many researchers [32–35]. In 
the dephosphorylated state, it acts as a transcriptional 
transactivator to regulate the expression of several genes 
including GSK3β [36]. Once phosphorylated, it interacts 
with a plethora of other cellular adaptors, heavily influ-
encing the cellular machinery. In an attempt to identify 
the intracellular interacting partners of phosphorylated 
AICD, we found twenty novel AICD interacting partners 
from mouse neuroblastoma cells [37]. Molecular func-
tions of several of these interactors, for example ApoA4, 
GAB2, HSPA8, vimentin etc., could be correlated to AD, 
revalidating that AICD and its interactions have implica-
tions towards AD pathophysiology. In a different study, 
we could identify AICD interacting proteins from CSF of 
AD patients and also compare the differential expressions 
of these interactors with respect to that of non-demented 
control patients [38]. Keeping the need for identifying 
the indirect candidates involved besides the direct ones 
for in-depth exploration of the molecular networks of 
the disease, we transfected AICD in mouse and human 
neuroblastoma cell lines and identified differential 
expressions of proteins belonging to diverse molecular 
pathways [39], for example, ER-stress (GRP78), struc-
tural remodeling (vimentin) and general stress (HSP90β, 
HSPA8).
Clinical proteomics in spinal cord injury
Acute traumatic injury of the spinal cord resulting in par-
tial or total deficits in sensory and/or motor functions 
is widely prevalent worldwide and leads to considerable 
decline in the quality of life [40]. Though relative annual 
incidences of SCI vary with the geographical region and 
the time period of the study [41], studies show that global 
average incidence is highest in Asia [40] with 43.8 per-
sons per million people afflicted. Traffic accidents [42], 
fall from height [43] and violence [44] constitute some of 
the major reasons for SCI.
Autonomic dysfunctions that follow SCI set the major 
decline in the quality of life of afflicted persons. An injury 
above the C3 level in the vertebral column may lead to 
immediate cardiac arrest necessitating assisted respira-
tion [45]. While the autonomic deregulations may last 
for a period of weeks after an injury, grossly the patho-
physiology of SCI is divided into primary and secondary 
injuries. The initial trauma to the spinal cord is called pri-
mary injury and it is a prognostic indicator of SCI [46]. 
Following the primary injury, secondary injury sets in 
[47] and may last from months to years. This phase wit-
nesses a plethora of degenerative phenotypes attributed 
to multitudes of molecular responses to injury [48].
Therefore, in spinal cord injury research, it is very 
important to get a clear picture of the molecular anatomy 
at the vicinity of the injury. On the other hand, for the 
peripheral nerve injuries, which comprise a greater sub-
set of neuronal injuries, study of molecular parameters 
promoting axonal regeneration is of paramount impor-
tance [49]. Axon forms an important tissue to analyse 
changes following an injury. This is because of a temporal 
sequence of three events promoting neuron regeneration: 
discharge of axonal potentials induced by injury, inter-
rupted normal supply of retrogradely transported target-
derived factors, and retrograde injury signals travelling 
from the injury site back to the cell body, also called posi-
tive injury signals [50]. Here, the necessity of biomarker 
analysis is born. Especially, proteomics approaches are 
preferred to those of genomics in the domain of axonal 
regeneration and degeneration because changes in axons 
often occur without any transcriptional events in the cell 
body, following a pathological condition [5]. Moreover, 
a large number of PTMs to proteins accompany axonal 
degeneration and regeneration, which has been rightfully 
termed as a ‘postgenomics’ problem. A series of elegant 
work from the group of Perlson et  al., beginning with 
proteomics approach, showed that vimentin is translated 
at the site of axonal injury [51], it is retrogradely trans-
ported from the site of injury to the cell body on dynein 
motor [52] and binds with ERK preventing its dephos-
phorylation [53].
Clinical proteomics tools to discover molecular 
interplay post SCI
Application of proteomics in biomarker analysis in trau-
matic SCI has found inflammatory cytokines at elevated 
levels and documented the elevation of tau, S100beta, 
GFAP and MCP-1 in a severity dependent fashion [54]. 
Commonly deregulated proteins as fished out by prot-
eomics studies, include plasma proteins, HSPs, glyco-
lytic enzymes, antioxidants and proteins participating in 
DNA damage and repair, protein degradation, cell sign-
aling and structural proteins [55, 56]. Transgelin and 
protein S100-A11 were found to be biomarkers of blad-
der healing in the secondary injury phase of rats [57]. An 
early study with insoluble segments of injured rat spinal 
cord using 2-DE followed by MALDI-TOF/TOF found 
decreased abundance of pyruvate dehydrogenase beta, 
Page 4 of 9Sengupta et al. Clin Proteom  (2016) 13:10 
aconitase 2, fumarate hydratase 1, and ATP synthase 
subunit 6, which can lead to ATP depletion. On the other 
hand, antioxidant proteins such as catalase and PRDX-1 
were decreased [58]. Implication of antioxidants were 
further shown with the aid of 2-DE where decreased 
abundance of catalase (CAT) and Mn-superoxide dis-
mutase (Mn-SOD) were detected at the lesion centre 
14 days post SCI in rats [59]. Additionally galectin-3, beta 
actin, actin regulatory protein (CAPG) and F-actin cap-
ping protein subunit beta (CAPZB) were found increased 
at similar time period post injury suggesting a decrease 
in antioxidant function and increase in growth inhibit-
ing proteins post SCI. Treatment with acidic fibroblast 
growth factor (aFGF) down-regulated regeneration-
blocking secondary phase proteins like S100beta, GFAP 
and the keratin sulphate proteoglycan, lumican, as dem-
onstrated using proteomic approaches in rat SCI model 
[60]. Tyrosine 3-monooxigenase/Tryptophan 5-monoox-
igenase activation protein (YWHAZ), a hub of several 
signal transduction pathways, glutathione peroxidise 3, 
involved in detoxifying hydrogen peroxide and S100a8, 
which is zinc and calcium binding protein involved in 
immune response regulation, were found to be biomark-
ers of severity in rats at 24  h post injury [61]. Afjehi-
Sadat et  al. showed higher abundance of 14-3-3 epsilon 
protein, dynein light chain 1, and tubulin beta-5 chain 
and decreased abundance of adenylyl cyclase associated 
protein 1, dihydropyrimidinase-related protein 2, F-actin 
capping protein subunit beta, glyceraldehyde-3-phos-
phate dehydrogenase, stress-induced phosphoprotein 
1 and transthyretin in injured tissue of SCI in rats. Free 
oxygen radical attack on proteins in SCI was indicated by 
PTM analysis [62].
Limitations of identifying a larger number of proteins 
using conventional 2-DE methods prompted researchers 
to use multiplex array proteomics to analyse low abun-
dance proteins from CSF available in small volumes. A 
cytokine profiling from CSF of cervical SCI rats at 12 days 
post injury revealed MMP-8 to be an elevated biomarker 
[63]. Proteomics approaches have been employed to 
decipher the temporal changes of protein expression 
after SCI. This is particularly important because protein 
expression pattern is drastically disturbed following an 
injury and there is a prolonged persistence of irregulari-
ties in protein expression patterns thereafter. Zhu et  al. 
found that 24 h post injury is the key time when the pro-
tein expression changes drastically in a rabbit SCI model 
[64].
Use of labeling with iTRAQ reagent coupled with prot-
eomics approaches have derived significant results in the 
domain of SCI. LC–MS/MS with iTRAQ reagent labeling 
identified proteins involved in ubiquitination, endocy-
tosis and exocytosis, energy metabolism, inflammatory 
response, oxidative stress, cytoskeletal disruption, and 
vascular damage as altered significantly at 24  h after 
SCI in rats [65]. Heat shock proteins were significantly 
differentially expressed in a rat model of SCI found in a 
study using iTRAQ and 2D LC–MS/MS [66] pointing 
to their potential role after SCI. 2-DE followed by nano 
ultra-high performance liquid chromatography-elec-
trospray tandem mass spectrometry (NanoUPLC–ESI–
MS/MS) identified proteins associated with apoptosis, 
nerve signal transduction and metabolism to be differ-
entially regulated in rat SCI followed by treatment with 
basic fibroblast growth factor long circulation liposome 
(bFGF + LCL) [67].
Proteomics of SCI in India
Currently, even though there are numerous studies being 
done on various, mostly rehabilitative [68], epidemiologi-
cal [69], financial [70], clinical [71, 72] and surgical [73] 
aspects of SCI in India, use of proteomics approach to 
get into the molecular level has been done only in our 
laboratory.
We have been focusing on the molecular interplay 
occurring in the secondary phase of SCI, which essen-
tially manifests as the various phenotypic dysfunc-
tions associated with this stage. For this purpose we 
conducted a clinical sampling with 14 SCI patients at 
1–8  days post injury and contrasted their cerebrospi-
nal fluid (CSF) from complete and incomplete injury 
types. The injury severities were ascertained using the 
American Spinal Injury Association (ASIA) Impairment 
Scale (AIS) [74]. 2-DE followed by MALDI MS/MS was 
employed to identify CSF proteins from SCI patients 
and furthermore, 2D-DIGE was conducted to contrast 
the different AIS samples of CSF [56]. Forty-nine pro-
teins were identified from CSF of SCI cases. Eight of 
them were differentially abundant (≥±1.5 fold) among 
AIS A (complete injury) and AIS C (incomplete injury) 
CSF samples. The status of the differentially abundant 
proteins among the AIS groups was further checked 
for CSF taken at 15–60 post injury from an additional 
6 patients.
Application of bioinformatics tools to the identified 
proteins from SCI CSF yielded a protein–protein inter-
action network (PPIN) consisting of the identified pro-
teins and their secondary interactors. From this network, 
interaction modules were created where protein mem-
bers within a module interact more with one another 
than with proteins outside of the module. We adopted 
the Newman–Girvans modularization (NGM) algorithm 
[75–77]. Thus a modularised network was formed. The 
network was further enriched [78] to identify biological 
functions associated with the modules. This was done 
using GeneCodis3 [79].
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Finally identifying the modules where the differentially 
abundant proteins were found, we zeroed in on the per-
turbed biological pathways post SCI at the secondary 
phase. The significantly perturbed pathways were mRNA 
metabolism, protein phosphorylation, iron transport, 
lipid and ATP catabolism, tRNA and rRNA transcription 
and DNA repair. We therefore identified some molecular 
pathways that lose their balance post SCI and we started 
off with identifying the entire proteome of SCI CSF and 
gradually narrowing down from there. The employment 
of proteomics tools was immensely useful in our case as 
we did not start with any particular protein or pathway 
in mind. This holistic approach with gradual focus on the 
important results is thus a preferred choice not only in 
the domain of biomarker discovery but also in a situation 
like ours, where a molecular dissection is being carried 
out.
Neuromyelitis optica
Neuromyelitis optica (NMO) or Devic’s disease is an 
autoimmune inflammatory disease that affects the cen-
tral nervous system, predominantly the optic nerves and 
spinal cord [80, 81]. Devic’s disease, because of its resem-
blance with multiple sclerosis was initially speculated to 
be a variant of the latter. But with advances in clinical 
and immunological studies, the existence of NMO as a 
distinct disease has been established [82, 83]. The clinical 
features associated with the disease include optic neuri-
tis and transverse myelitis [84]. The disease can be either 
monophasic or relapsing [84]. In 2006 after the discovery 
of anti AQP4-IgG [85] the initially proposed diagnostic 
criteria for NMO was revised. The seropositivity of NMO 
autoantibody together with optic neuritis and longitudi-
nal extensive transverse myelitis was then considered as 
the defining parameter for NMO [86].
As compared to other neurodegenerative disorders 
the global distribution of NMO is rather limited [87]. Its 
prevalence among Caucasians is low where the abun-
dance of multiple sclerosis is high [88, 89]. Higher inci-
dence of NMO has been reported among south Asian 
countries like India, Korea and the Philippines [90]. 
Demographic studies reveal that women are more predis-
posed to the disease than men [91, 92]; this is true even 
for the paediatric cases [93]. The disease mainly afflicts 
young adults with ages ranging mostly under 18  years 
although there have been some reports of late onset too 
[94, 95]. The administration of immunosuppressive drugs 
has been the major treatment for the disease [96].
Advances in proteomic study of NMO
The presence of serum antibody NMO-IgG among the 
patients [85] was initially considered to be highly spe-
cific for disease confirmation but later it was seen that 
all patients were not NMO-IgG seropositive. Evidently 
it became crucial to look for other biochemical mark-
ers of the disease. Proteomic analysis which has been 
extensively employed in biomarker discovery for simi-
lar diseases like multiple sclerosis [97] was extended 
thereafter for the detailed study of NMO. The major 
study of NMO proteomics has been conducted in CSF, 
blood and urine. The insight into different CNS diseases 
is provided by CSF proteomics [98, 99]. CSF compara-
tive proteomics with multiple sclerosis, NMO and nor-
mal patients by Jiang et  al. led to identification of four 
proteins namely—Pre-Albumin (PA), Keratin1, transfer-
rin and Keratin 9 [100]. PA had high expression levels 
among multiple sclerosis patients while Keratin 1 was 
significantly increased in NMO patients. Transferrin 
(Tf ) is a crucial marker for blood–brain-barrier (BBB) 
damage [101] and its high levels in NMO are indica-
tive of the damage caused to the blood–brain-barrier 
because of NMO pathogenesis. In a separate study 
by Bai et  al., proteome analysis in the CSF of NMO 
patients in comparison to control group revealed the 
up regulation of Neurofilament, Haptoglobin, immu-
noglobulin kappa chain C region (IGKC) and immuno-
globulin heavy chain gamma 3 (IGHG3) levels [102]. In 
the same group of patients there was downregulation in 
alpha-1β-glycoprotein (A1BG), fibrinogen gamma chain 
(FGG), apolipoprotein A-IV (ApoA-IV), apolipoprotein 
E (ApoE), transthyretin (TTR) and vitamin-D binding 
protein (DBP) levels. Among NMO patients the rise in 
IGKC and IGHG3 and the downregulation of ApoA-IV 
levels hints at the involvement of immunological mecha-
nisms in disease progression. Neurofilament, a protein 
localised in the axon usually reflects the axonal health 
[103]. The expression of this protein in NMO poses it as 
a biomarker for the disease. In another serum proteomic 
study by Jiang et al., there was a two-fold elevation in the 
levels of haptoglobin in NMO patients in comparison to 
control as well as multiple sclerosis cases [104]. Nielson 
et al. revealed an increase in levels of immunoglobulins 
Ig-G3, Ig-K and Ig-L in the urine proteome of NMO sub-
jects in comparison to healthy subjects [105]. The differ-
ential expression profiles that have been obtained using 
two dimensional (2D) gel electrophoresis in combina-
tion with mass spectrometry, in totality, projects several 
probable biomarkers that would guide in the diagnosis 
of NMO.
The futuristic approach of such proteomic profiling 
studies is to investigate the potential cellular players that 
are differentially expressed among the seropositive and 
seronegative groups of NMO patients. This would be 
extremely crucial both in terms of classification as well 
as treatment of these two different subgroups of NMO 
patients.
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Conclusions
The endeavor in our laboratory for the past 8  years has 
been centered on understanding mechanisms leading 
to nervous system trauma—be it a disease or an injury. 
Starting with Alzheimer’s disease, additional require-
ment of biomarkers aside from the most basic CSF ones, 
tau, phosphorylated tau and Aβ-42, prompted proteom-
ics based research in this domain. The search identified 
several plasma and CSF biomarkers for AD. Further on, 
research from our laboratory has highlighted the interac-
tion proteome of AICD in a cell based and clinical model. 
The follow-up studies dealing with candidate biomark-
ers identified through proteomics which are function-
ally linked to important biochemical pathways, are very 
crucial for the advancement of understanding the disease 
pathophysiology.
Coming on to spinal cord injury, the bulk of biomarker 
discovery has always employed proteomics methods. 
Since the lack of primary neuron regeneration beyond 
the injury point remains evasive, there is tremendous 
ongoing research in this area. Proteomics research in 
past decades have highlighted the role of cytokines in 
trauma pathology as well as those of  plasma proteins, 
HSPs, glycolytic enzymes, antioxidants and DNA dam-
age and repair proteins, protein degradation, cell signal-
ing and structural proteins. Research from our laboratory 
has highlighted several perturbed molecular pathways 
post SCI, which include protein phosphorylation, DNA 
repair, mRNA metabolism, iron transport tRNA and 
rRNA transcription and lipid and ATP catabolism.
Neuromyelitis optica is a relatively less studied patho-
logical condition when compared to the previous two 
and we have just started working with clinical samples. 
Anti AQP4-IgG was discovered in 2006 as a biomarker 
for NMO. A curious feature of this disease is that in sev-
eral cases it has been observed that patients with NMO 
were not seropositive for the NMO-IgG. This prompted 
us to look for reliable candidate biomarkers and although 
studies have been limited so far, proteomics approaches 
look promising in this particular upcoming area of neu-
rological disorder.
While working with nervous system we believed that 
proteomics approaches favor the initial ‘biomarker dis-
covery’ stage of a research paradigm of a disease. It is 
particularly useful in diseases of the neurological dis-
orders or injury as CSF and plasma form the common 
target sources of protein profile detection in the initial 
and also subsequent stages of identification of pathology 
mechanisms. Figure  1 represents the research strategies 
adopted by the Mukhopadhyay laboratory to study the 
three neuro-pathological conditions, AD, SCI and NMO.
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Fig. 1 A representative diagram of the paradigm adopted by our 
laboratory in neurodegeneration research. Starting with Alzheimer’s 
disease, in proteomics domain, we found out the interacting partners 
of AICD in CSF and AICD-transfected human and mouse cell lines. 
Twenty novel AICD interactors were found in mouse neuroblastoma 
cells. The study was further followed up in human CSF, where differ-
entially expressed AICD interactors were found out. Finally, differential 
expression of AICD interactors were studied in human and mouse 
neuroblastoma. Moving forward to spinal cord injury, we looked at 
differentially abundant proteins in the CSF of SCI patients with dif-
ferent severity grades of injury. An interaction network was created 
using the proteins found in the CSF of AIS grade A injury and modu-
larization of the same revealed a number of perturbed pathways. 
Finding putative disease markers for the rather evasive successful 
marker hunting in neuromyelitis optica remains a future perspective
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